Therapies in Aicardi-Goutières syndrome

Clinical and Experimental Immunology

Volumn 175, Issue 1, 2014, Pages 1-8

  Crow, Y J ^a,b   Vanderver, A ^c   Orcesi, S ^d   Kuijpers, T W ^e   Rice, G I ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Aicardi Gouti res syndrome; Anti interferon antibodies; Interferonopathy; Reverse transcriptase inhibitors; Type I interferon

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; AZATHIOPRINE; IMMUNOGLOBULIN; INTERFERON; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NUCLEIC ACID; PREDNISONE; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

AICARDI GOUTIERES SYNDROME; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; AUTOIMMUNE DISEASE; BIOLOGY; CD4+ T LYMPHOCYTE; CEREBROSPINAL FLUID; CHILBLAIN; CYTOLOGY; DISEASE SEVERITY; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOREACTIVITY; INNATE IMMUNITY; INTERFERON INDUCTION; MOLECULAR BIOLOGY; MORBIDITY; MORTALITY; MYOCARDITIS; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE INJURY; UPREGULATION;

AICARDI-GOUTIÈRES SYNDROME; ANTI-INTERFERON ANTIBODIES; INTERFERONOPATHY; REVERSE TRANSCRIPTASE INHIBITORS; TYPE I INTERFERON;

AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; HUMANS; INTERFERON TYPE I; NERVOUS SYSTEM MALFORMATIONS;

EID: 84888880113     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12115     Document Type: Article

References (44)

1. Rice G, Patrick T, Parmar R etal. Clinical and molecular phenotype of Aicardi-Goutieres syndrome. Am J Hum Genet 2007; 81:713-725.
2. Crow YJ, Livingston JH. Aicardi-Goutieres syndrome: an important Mendelian mimic of congenital infection. Dev Med Child Neurol 2008; 50:410-416.
3. McEntagart M, Kamel H, Lebon P, King MD. Aicardi-Goutieres syndrome: an expanding phenotype. Neuropediatrics 1998; 29:163-167.
4. Orcesi S, Pessagno A, Biancheri R etal. Aicardi-Goutieres syndrome presenting atypically as a sub-acute leukoencephalopathy. Eur J Paediatr Neurol 2008; 12:408-411.
5. Aicardi J, Goutieres F. A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis. Ann Neurol 1984; 15:49-54.
6. Vogt J, Agrawal S, Ibrahim Z etal. Striking intrafamilial phenotypic variability in Aicardi-Goutieres syndrome associated with the recurrent Asian founder mutation in RNASEH2C. Am J Med Genet A 2013; 161A:338-342.
7. Tolmie JL, Shillito P, Hughes-Benzie R, Stephenson JB. The Aicardi-Goutieres syndrome (familial, early onset encephalopathy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis). J Med Genet 1995; 32:881-884.
8. Prendiville JS, Crow YJ. Blue (or purple) toes: chilblains or chilblain lupus-like lesions are a manifestation of Aicardi-Goutieres syndrome and familial chilblain lupus. J Am Acad Dermatol 2009; 61:727-728.
9. Ramesh V, Bernardi B, Stafa A etal. Intracerebral large artery disease in Aicardi-Goutieres syndrome implicates SAMHD1 in vascular homeostasis. Dev Med Child Neurol 2010; 52:725-732.
10. du Moulin M, Nurnberg P, Crow YJ, Rutsch F. Cerebral vasculopathy is a common feature in Aicardi-Goutieres syndrome associated with SAMHD1 mutations. Proc Natl Acad Sci USA 2011; 108:E232; author reply E233.
11. Xin B, Jones S, Puffenberger EG etal. Homozygous mutation in SAMHD1 gene causes cerebral vasculopathy and early onset stroke. Proc Natl Acad Sci USA 2011; 108:5372-5377.
12. Thiele H, Du Moulin M, Barczyk K etal. Cerebral arterial stenoses and stroke: novel features of Aicardi-Goutieres syndrome caused by the Arg164X mutation in SAMHD1 are associated with altered cytokine expression. Hum Mutat 2010; 31:E1836-1850.
13. Crow YJ. Type I interferonopathies: a novel set of inborn errors of immunity. Ann NY Acad Sci 2011; 1238:91-98.
14. Lebon P, Badoual J, Ponsot G, Goutieres F, Hemeury-Cukier F, Aicardi J. Intrathecal synthesis of interferon-alpha in infants with progressive familial encephalopathy. J Neurol Sci 1988; 84:201-208.
15. Akwa Y, Hassett DE, Eloranta ML etal. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol 1998; 161:5016-5026.
16. Crow YJ, Hayward BE, Parmar R etal. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus. Nat Genet 2006; 38:917-920.
17. Crow YJ, Leitch A, Hayward BE etal. Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutieres syndrome and mimic congenital viral brain infection. Nat Genet 2006; 38:910-916.
18. Rice GI, Bond J, Asipu A etal. Mutations involved in Aicardi-Goutieres syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Genet 2009; 41:829-832.
19. Rice GI, Kasher PR, Forte GM etal. Mutations in ADAR1 cause Aicardi-Goutieres syndrome associated with a type I interferon signature. Nat Genet 2012; 44:1243-1248.
20. Rice G, Newman WG, Dean J etal. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome. Am J Hum Genet 2007; 80:811-815.
21. Haaxma CA, Crow YJ, van Steensel MA etal. A de novo p.Asp18Asn mutation in TREX1 in a patient with Aicardi-Goutieres syndrome. Am J Med Genet A 2010; 152A:2612-2617.
22. Abe J, Izawa K, Nishikomori R etal. Heterozygous TREX1 p.Asp18Asn mutation can cause variable neurological symptoms in a family with Aicardi-Goutieres syndrome/familial chilblain lupus. Rheumatology (Oxf) 2013; 52:406-408.
23. Tungler V, Silver RM, Walkenhorst H, Gunther C, Lee-Kirsch MA. Inherited or de novo mutation affecting aspartate 18 of TREX1 results in either familial chilblain lupus or Aicardi-Goutieres syndrome. Br J Dermatol 2012; 167:212-214.
24. Crow YJ, Rehwinkel J. Aicardi-Goutieres syndrome and related phenotypes: linking nucleic acid metabolism with autoimmunity. Hum Mol Genet 2009; 18:R130-136.
25. Yang YG, Lindahl T, Barnes DE. Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell 2007; 131:873-886.
26. Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 2008; 134:587-598.
27. Gall A, Treuting P, Elkon KB etal. Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity 2012; 36:120-131.
28. Reijns MA, Rabe B, Rigby RE etal. Enzymatic removal of ribonucleotides from DNA is essential for mammalian genome integrity and development. Cell 2012; 149:1008-1022.
29. Lebon P, Meritet JF, Krivine A, Rozenberg F. Interferon and Aicardi-Goutieres syndrome. Eur J Paediatr Neurol 2002; 6 (Suppl. A):A47-53; discussion A55-8, A77-86.
30. De Laet C, Goyens P, Christophe C, Ferster A, Mascart F, Dan B. Phenotypic overlap between infantile systemic lupus erythematosus and Aicardi-Goutieres syndrome. Neuropediatrics 2005; 36:399-402.
31. D'Arrigo S, Riva D, Bulgheroni S etal. Aicardi-Goutieres syndrome: description of a late onset case. Dev Med Child Neurol 2008; 50:631-634.
32. Kuijpers TW. Aicardi-Goutieres syndrome: immunophenotyping in relation to interferon-alpha. Eur J Paediatr Neurol 2002; 6 (Suppl. A):A59-64; discussion A65-6, A77-86.
33. Yao Y, Higgs BW, Morehouse C etal. Development of potential pharmacodynamic and diagnostic markers for anti-IFN-alpha monoclonal antibody trials in systemic lupus erythematosus. Hum Genomics Proteomics 2009; 1: doi: 10.4061/2009/374312.
34. Engel ME, Hiebert SW. The enemy within: dormant retroviruses awaken. Nat Med 2010; 16:517-518.
35. Beck CR, Collier P, Macfarlane C etal. LINE-1 retrotransposition activity in human genomes. Cell 2010; 141:1159-1170.
36. Huang CR, Schneider AM, Lu Y etal. Mobile interspersed repeats are major structural variants in the human genome. Cell 2010; 141:1171-1182.
37. Iskow RC, McCabe MT, Mills RE etal. Natural mutagenesis of human genomes by endogenous retrotransposons. Cell 2010; 141:1253-1261.
38. Yan N, Regalado-Magdos AD, Stiggelbout B, Lee-Kirsch MA, Lieberman J. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat Immunol 2010; 11:1005-1013.
39. Laguette N, Sobhian B, Casartelli N etal. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011; 474:654-657.
40. Hrecka K, Hao C, Gierszewska M etal. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011; 474:658-661.
41. Baldauf HM, Pan X, Erikson E etal. SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nat Med 2012; 18:1682-1687.
42. Cerritelli SM, Crouch RJ. Ribonuclease H: the enzymes in eukaryotes. FEBS J 2009; 276:1494-1505.
43. Doitsh G, Cavrois M, Lassen KG etal. Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell 2010; 143:789-801.
44. Beck-Engeser GB, Eilat D, Wabl M. An autoimmune disease prevented by anti-retroviral drugs. Retrovirology 2011; 8:91.